^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPX-701

    i
    Other names: BPX-701, BPX701, BPX 701
    Associations

    News

    Trials
    Company:
    Bellicum, Leiden University Medical Center
    Drug class:
    PRAME inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma (clinicaltrials.gov)
    P1/2, N=4, Terminated, Bellicum Pharmaceuticals | N=28 --> 4 | Unknown status --> Terminated; company decision
    Enrollment change • Trial termination • Metastases
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    PRAME expression
    |
    BPX-701 • rimiducid (AP1903)